For example, the UK National Institute for Health and Care Excellence (NICE) does not recommend the ALK inhibitor, Xalkori® for use in ALK-driven NSCLC, based on the ruling that the drug does not offer value for money. Here, ALK is linked to non-small cell lung carcinoma.